Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-26-037971
Filing Date
2026-08-14
Accepted
2026-08-14 07:30:56
Documents
66
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 1120189
2 EX-31.1 ex31-1.htm EX-31.1 17848
3 EX-31.2 ex31-2.htm EX-31.2 18974
4 EX-32.1 ex32-1.htm EX-32.1 6933
5 EX-32.2 ex32-2.htm EX-32.2 6827
  Complete submission text file 0001493152-26-037971.txt   5293214

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20260630.xsd EX-101.SCH 37600
7 XBRL CALCULATION FILE ltrn-20260630_cal.xml EX-101.CAL 51142
8 XBRL DEFINITION FILE ltrn-20260630_def.xml EX-101.DEF 132205
9 XBRL LABEL FILE ltrn-20260630_lab.xml EX-101.LAB 294720
10 XBRL PRESENTATION FILE ltrn-20260630_pre.xml EX-101.PRE 240665
69 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 832607
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 261276083
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)